# Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

> **NCT01135329** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- Lymphoma
- Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01135329
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The stopping rule was met and hence the study was closed
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01135329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01135329, "Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01135329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*